Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis

British Medical Journal

Volumn 330, Issue 7504, 2005, Pages 1366-1369

  Hippisley Cox, Julia ^a   Coupland, Carol ^a  

^a Tower Building ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; ETORICOXIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; VALDECOXIB; PROSTAGLANDIN SYNTHASE INHIBITOR;

ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GENERAL PRACTICE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SMOKING; ADULT; AGED; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COHORT ANALYSIS; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COHORT STUDIES; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 22444441665     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.38456.398507.8F     Document Type: Article

References (10)

1. Topol E, Falk G. A coxib a day won't keep the doctor away. Lancet 2004;364:640-1.
2. Farkouh ME, Kishner H, Harrington RA, Ruland S, Verheught FW, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-84.
3. National Institute for Clinical Excellence. Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. London: NICE, 2001, (Technology appraisal guidance No 27.)
4. Hippisley-Cox J, Stables D, Pringle M. QRESEARCH - a new general practice database for research. Journal of Informatics in Primary Care 2004;12:49-50.
5. Ray W, Stein M, Hall K, Daugherty J, Griffin M. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: observational cohort study. Lancet 2002;359:118-23.
6. Juni P, Nartey L, Reichenback S, Sterchi R, Dieppe P, Matthias E. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-9.
7. Soloman D, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002;162:1099-104.
8. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002;162:1105-10.
9. Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163:481-6.
10. MacDonald TM, Morant SV, Goldstein JL, Burke TA, Pettitt D. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal antiinflammatory drugs. Gut 2003;52:1265-70.